Slide 1: Financial Results Q2:2026 Slide Supplement
FINANCIAL RESULTS Q2:2026 SLIDE SUPPLEMENT NASDAQ: TKNO August 5, 2026
Slide 2: Forward-looking statements and use of non-GAAP financial measures
Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, b
Slide 3: Agenda
Agenda • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2026 Outlook Matt Lowell, Chief Financial Officer • Q&A © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 3
Slide 4: We Make Solutions Possible
WE MAKE SOLUTIONS POSSIBLE Leading provider of critical reagents for the discovery, development, and commercialization of novel therapies and diagnostics 2026E REVENUE GUIDANCE 2026E REVENUE GROWTH PROJECT ADJUSTED (MIDPOINT) EBITDA POSITIVE $45-47M 14% 2027 ACTIVE CLINICAL CUSTOMER NUMBER OF CUSTOM
Slide 5: Our products are fundamental to the life sciences industry
Our products are fundamental to the life sciences industry LIQUID MICROBIAL MOLECULAR BIOLOGY AGAR PLATES CULTURE MEDIA REAGENTS AND SUPPLEMENTS Extensive selection of standard Wide variety of liquid media Offering a vast range of product types, and specialty pre-poured agar plates for and broths to
Slide 6: Primary End Market Segments
2025 REVENUE BREAKDOWN Primary End Market Segments REVENUE BY END MARKET SEGMENT FY:2025 5% Non-Product APPROX. APPROX. APPROX. Revenue 1,000 * 400 * 1,900 * ACCOUNTS ACCOUNTS ACCOUNTS BIOPHARMA AND ~15% LIFE SCIENCE TOOLS AND OTHER MARKET Other Market CONTRACT DIAGNOSTICS SEGMENTS Segments MANUFACT
Slide 7: Revenue by Product Type and Customer End Market
Revenue by Product Type and Customer End Market TotalOTHER 2024 Revenue by Product Type ~5%and End Market 2025 REVENUE BREAKDOWN CLINICAL • Lab Essentials: ~75% of 2025 Revenue SOLUTIONS ▪ Catalog product revenue comprises ~75% ~20% 15% CLINICAL ▪ Custom product revenue comprises ~25% (includes RUO+
Slide 8: Historical Customer Metrics by Product Category
Historical Customer Metrics by Product Category NON-GAAP FIGURES: LAB ESSENTIALS CLINICAL SOLUTIONS Number of Customers1 3,374 3,255 3,045 60 2,754 2,826 48 2,008 34 21 24 13 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 Average Revenue per $10,578 $10,191 $369 $352 $9,871 $9,761 $9,48
Slide 9: Why we win
Why we win CATALOG BUSINESS FASTER AS A FOUNDATION SMALLER CUSTOM BATCH TURNAROUND TIME SIZES Relative Annual Spend Initial Build Sizes for Custom Research Time from Order to Shipment by Account Type in 2025 and Clinical Orders for Custom Orders 44X 10,000 L MONTHS QC 1,000 L Typical batch size for
Slide 10: Build-Tek Custom Configurator
NEW AI-POWERED ASSISTANT Build●TekTM Custom Configurator Build complex custom product requests in minutes with Teknova’s interactive reagent assistant 3 minutes 3 days 30 years Build a complete Submit your configuration Proven custom reagent custom order with just and our team returns a manufacturin
Slide 11: Q2:26 Financials
teknova: Q2:26 Financials
Slide 12: Q2:2026 Revenue Highlights
Q2:2026 Revenue Highlights Revenue by Category ($M) KEY HIGHLIGHTS $12.2 • Total first quarter revenue up 18% compared to the same period in prior $10.3 18% y/y $2.4 year $2.1 • Lab Essentials increased 18% compared to the same period in prior year • Clinical Solutions increased 18% compared to the
Slide 13: Q2:2026 Income Statement Highlights
Q2:2026 Income Statement Highlights Gross Margin (%) Total OpEx ($M) $7.4 $7.8 38.7% 40.1% Q2:2025 Q2:2026 Q2:2025 Q2:2026 Adjusted EBITDA1 ($M) Diluted EPS ($) ($0.7) ($0.06) ($0.8) ($0.07) Q2:2025 Q2:2026 Q2:2025 Q2:2026 1 Adjusted EBITDA is non-GAAP and adds back stock-based compensation and any
Slide 14: Q2:2026 Cash Flow and Balance Sheet Highlights
Q2:2026 Cash Flow and Balance Sheet Highlights Capital Expenditure ($M) Free Cash Flow1 ($M) ($0.6) ($2.3) $0.2 $0.1 Q2:2025 Q2:2026 Q2:2025 Q2:2026 Cash, Cash Equivalents, and Short-Term Investment was $17.4M as of June 30, 2026 1 Free Cash Flow equals cash provided by (used in) operating activitie
Slide 15: Quarterly Financial Trends
Quarterly Financial Trends Gross Margin1 (%) Total OpEx ($M) $10.2 $7.9 $7.8 $8.0 $7.9 $8.1 $7.8 $7.5 $7.4 $7.2 39% 40% 31% 32% 34% 29% 30% 31% $8.9 24% 23% $7.8 $7.5 $7.8 $8.0 $7.4 $7.2 $7.4 $8.1 $7.8 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3:25 Q4:25 Q1:26 Q2:26 Q1:24 Q2:24 Q3:24 Q4:24 Q1:25 Q2:25 Q3
Slide 16: 2026 Outlook and Capital Runway
2026 Outlook and Capital Runway GUIDANCE • Raising fiscal 2026 outlook for revenue and improving outlook for Free Cash Outflow • Anticipate total revenue of $45 million to $47 million for fiscal year ending December 31, 2026 (“2026”), up 14% y/y at the midpoint • Targeting Free Cash Outflow of less
Slide 17: Supplemental Non-GAAP Reconciliations
Supplemental Non-GAAP Reconciliations
Slide 18: Non-GAAP Reconciliations
Non-GAAP Reconciliations ALPHA TEKNOVA, INC. Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures (unaudited) (in thousands) © 2026 Alpha Teknova, Inc. ● Financial Results | Q2:2026 ● Slide Supplement 18
Slide 19: teknova:
teknova: